Search - tctmd.com

Displaying 621 - 640 of 855

Sort: Relevancy | Date

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Michael O'Riordan

October 29, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Conference News TCT 2019

COAPT at 3 Years: Crossover Patients See Benefits From MitraClip

Shelley Wood

September 28, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Shelley Wood

September 28, 2019

Presentation TCT 2019

Designing Controlled Trials for Shock Devices: Population Targets and Safety and Effectiveness Considerations

Presenter: Anthony Gershlick

September 27, 2019

Presentation TCT 2019

Industry Perspectives on Controlled Trials for Shock Devices

Presenter: Seth Bilazarian

September 27, 2019

Presentation TCT 2019

Industry View on Controlled Trials for Heart Failure and Shock Devices

Presenter: William Abraham

September 27, 2019

Presentation TCT 2019

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Presenter: Bram Zuckerman

September 27, 2019

News Conference News HFSA 2019

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

L.A. McKeown

September 24, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Todd Neale

September 13, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Industry News

Reduce Fmr Study Shows Cardiac Dimensions’ Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure

September 12, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

Advertisement

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

TCTMD’s Top 10 Most Popular Stories for October 2019

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

COAPT at 3 Years: Crossover Patients See Benefits From MitraClip

TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL

Designing Controlled Trials for Shock Devices: Population Targets and Safety and Effectiveness Considerations

Industry Perspectives on Controlled Trials for Shock Devices

Industry View on Controlled Trials for Heart Failure and Shock Devices

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Reduce Fmr Study Shows Cardiac Dimensions’ Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content